Erbulozole
Erbulozole (R55104) is a congener of the microtubule inhibitor tubulozole. It is undergoing phase I clinical trials as a chemotherapeutic agent.[1]
Clinical data | |
---|---|
Other names | Erbuzole |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C24H27N3O5S |
Molar mass | 469.56 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Synthesis
gollark: Well, Windows *is* quite bad.
gollark: Actually, I say many words containing h.
gollark: Bee you.
gollark: <@805534998660775986> unbully <@258639553357676545>
gollark: https://minoteaur-legacy.osmarks.net/view/welcome
References
- Van Belle SJ, Distelmans W, Vandebroek J, Bruynseels J, Van Ginckel R, Storme GA (1993). "Phase I trial of erbulozole (R55104)". Anticancer Research. 13 (6B): 2389–91. PMID 8135472.
Other reading
- Distelmans W, VanGinckel P, Heeres J, Van der Veken LJ (1991). "Erbulozole. Antineoplastic, Microtubule inhibitor". Drugs Future. 16 (6): 577.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.